Haemonetics expands use of Arryx's optical trapping technology:
This article was originally published in Clinica
Braintree, Massachusetts-based Haemonetics has received expanded rights to use Arryx's optical trapping technology in a broader range of blood processing applications. The amended agreement will see Haemonetics make a one-off payment of $3m to Arryx for increased access to its technology. In addition, as agreed in the previous contract, Arryx will also receive milestone payments totalling a potential $12.4m for development and regulatory achievements. The two companies first entered a collaborative agreement in October last year, in which Haemonetics was granted an exclusive worldwide licence to Arryx's technology. The former also made a $5m equity investment in the Chicago, Illinois company.